Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

Inclusion Criteria:

Male or female 18 - 85 years
Hospitalized for worsening heart failure, within 24 hours of initiating IV loop diuretic
Dyspnea due to heart failure, at rest or with minimal exertion
History of left ventricular ejection fraction (LVEF) ≤ 40%
Elevated brain natriuretic peptide (BNP) or N-terminal fragment BNP (NT-proBNP)

Exclusion Criteria:

Receiving IV vasopressor (excluding low dopamine), inotropic or mechanical support
Acute coronary syndrome (ACS)
Within 30 days prior to enrollment: cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation, ACS, coronary revascularization, transient ischemic attack (TIA) or stroke, sustained ventricular arrhythmia, or major surgery
Severe valvular stenosis, hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease
Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2